Saxenda & Victoza (Liraglutide)

Before there was Ozempic, before Wegovy made headlines, before anyone was talking about tirzepatide — there was liraglutide. It was the GLP-1 medication that proved this entire drug class worked for both diabetes and weight management.

Liraglutide doesn’t get the attention it used to. The newer medications produce more dramatic weight loss numbers and only require weekly injections instead of daily ones. But liraglutide has something the newer drugs can’t match: over a decade of real-world safety data, landmark cardiovascular evidence, and — as of 2025 — generic versions that make it more affordable than it’s ever been.

This page covers both liraglutide products: Victoza (for Type 2 diabetes) and Saxenda (for weight management). Same molecule, same daily injection, different approvals.

---

The Basics

Both products are made by Novo Nordisk. The active ingredient in both is liraglutide — a GLP-1 receptor agonist with a half-life of about 13 hours, which is why it requires daily injection instead of weekly.

Two Products, Same Molecule

Victoza was one of the first once-daily GLP-1 medications on the market. It’s approved for improving blood sugar control in adults with Type 2 diabetes, and later received an additional approval for reducing cardiovascular risk in adults with Type 2 diabetes and established heart disease.

Saxenda is the same molecule at a higher dose, approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related health condition. It’s also approved for adolescents aged 12 and older with obesity.[1]

---

How It’s Delivered

Both Victoza and Saxenda come as a multi-dose, pre-filled pen. Unlike the single-dose pens used by Mounjaro or Wegovy, one liraglutide pen contains multiple days’ worth of medication. You dial your dose using a selector on the pen.

The Pens

Victoza pen: Contains 18 mg of liraglutide in 3 mL. At the maximum dose of 1.8 mg/day, one pen lasts about 10 days. Comes in a 2-pen or 3-pen pack.

Saxenda pen: Same physical design — 18 mg in 3 mL. At the maximum dose of 3.0 mg/day, one pen lasts about 6 days. Comes in a 5-pen pack (one month’s supply at 3.0 mg/day).

Both use NovoFine or NovoFine Plus pen needles — the same ultra-thin needles used with Ozempic pens. A new needle attaches for each injection.

The injection goes under the skin in the abdomen, thigh, or upper arm. Same time each day, with or without food.[2]

The Daily Injection Reality

This is the biggest practical difference between liraglutide and the newer GLP-1 medications. Ozempic, Wegovy, Mounjaro, and Zepbound are all once-weekly injections. Liraglutide is once daily — every single day, 365 days a year.

For some people, this is a minor inconvenience. For others, it’s a dealbreaker. If you’ve been weighing liraglutide against a weekly injectable, the injection frequency is a legitimate factor in the decision.

---

Dosing Schedules

Victoza (for Type 2 Diabetes)

Saxenda (for Weight Management)

Saxenda’s dose escalation is faster than the newer medications — weekly increases instead of every four weeks. Each step adds 0.6 mg. If a particular dose causes significant side effects, your provider may slow the escalation or hold at a tolerable dose.

Important: The Saxenda prescribing information includes a specific guideline — if you haven’t lost at least 4% of your body weight after 16 weeks at the full 3.0 mg dose, your provider should consider whether to continue. The medication doesn’t work equally well for everyone, and this checkpoint helps identify who’s benefiting.[3]

---

What the Research Shows

Liraglutide’s clinical evidence goes back further than any other currently available GLP-1 medication. The key trials:

Blood Sugar Control (Victoza)

Victoza was tested in the LEAD trial program — six large clinical trials in patients with Type 2 diabetes. The results were consistently strong:

• HbA1c reduction: 1.0–1.5% at the 1.8 mg dose
• Patients reaching HbA1c below 7%: 50-60%, depending on the trial
• Victoza outperformed several other diabetes medications in head-to-head comparisons, including sulfonylureas and sitagliptin[4]

The LEADER Trial: Heart Protection

This is Victoza’s most important trial — and one of the most influential GLP-1 studies ever conducted.

LEADER enrolled 9,340 adults with Type 2 diabetes and high cardiovascular risk. They were randomized to Victoza 1.8 mg or placebo and followed for a median of 3.8 years.

The results:[5]

• Major cardiovascular events (heart attack, stroke, or cardiovascular death): reduced by 13%
• All-cause mortality (death from any cause): reduced by 15%
• Cardiovascular death alone: reduced by 22%

That last number — a 22% reduction in cardiovascular death — was what made the medical community take notice. LEADER was one of the first large trials to demonstrate that a GLP-1 medication doesn’t just improve blood sugar — it genuinely reduces the risk of dying from heart disease.

This trial is why Victoza received its cardiovascular indication from the FDA, and it helped establish the entire GLP-1 class as cardiovascular medications, not just diabetes drugs.

Weight Loss: The SCALE Trials (Saxenda)

Saxenda was studied in the SCALE trial program — four large trials focused on weight management.

SCALE Obesity and Prediabetes — the headline trial:

• Who: 3,731 adults with obesity or overweight with a weight-related condition, WITHOUT diabetes
• What: Saxenda 3.0 mg daily vs. placebo, both with lifestyle changes
• How long: 56 weeks

The results:[6]

SCALE Diabetes — in patients with Type 2 diabetes:

• Average weight loss: 5.8% vs. 2.0% with placebo

How It Compares to the Newer Medications

Let’s be honest about the numbers. The weight loss with Saxenda is real and meaningful, but it’s substantially less than what the newer medications achieve:

That’s a significant gap. The newer medications roughly double or nearly triple Saxenda’s weight loss results. This is partly due to longer-acting formulations, higher receptor potency, and — in tirzepatide’s case — dual receptor targeting.

This doesn’t make Saxenda ineffective. An 8% weight loss produces meaningful health improvements — reduced blood pressure, improved blood sugar, lower cardiovascular risk. But if maximum weight loss is the priority and you have access to the newer options, those numbers matter.

---

Side Effects

The side effect profile is similar to other GLP-1 medications but tends to be somewhat more pronounced, likely because the daily dosing means liraglutide’s effects don’t fully wear off between doses the way a weekly injection’s might.

The Numbers (from SCALE trials — Saxenda 3.0 mg)

That nausea number — 39% — is higher than what we see with the newer weekly medications at their therapeutic doses. However, like all GLP-1 side effects, most of the nausea occurs during dose escalation and improves over time. In the SCALE trials, about 6% of patients stopped Saxenda due to GI side effects.[7]

The Boxed Warning

Both Victoza and Saxenda carry an FDA boxed warning (the most serious type of drug warning) regarding thyroid C-cell tumors. In animal studies, liraglutide caused thyroid tumors in rats and mice. This has NOT been confirmed in humans — over a decade of human use has not shown an increased thyroid cancer risk — but the warning remains because the animal signal was strong enough that the FDA requires it.[8]

What this means for you: Liraglutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) — a specific type of thyroid cancer — or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a rare genetic condition. Your provider will ask about this before prescribing.

This same warning class applies to all GLP-1 medications, not just liraglutide — but since liraglutide was one of the first, the warning is most commonly associated with it.

---

The Generic Revolution

This is the biggest change in the liraglutide story in years — and it genuinely changes who can afford GLP-1 treatment.

What’s Happened

Starting in late 2024 and into 2025, generic versions of liraglutide became available from multiple manufacturers (including Hikma and Teva). These are FDA-approved generic equivalents — the same molecule, same doses, same pen delivery system.[9]

What It Costs Now

The generic isn’t cheap by normal medication standards, but compared to the branded versions or to the newer GLP-1 medications (which don’t have generics yet), it’s a meaningful step toward affordability.

Who This Matters For

Generic liraglutide is particularly relevant for:

• People without insurance coverage for the newer GLP-1 medications — if your insurance won’t cover Wegovy or Zepbound, generic liraglutide might be the most affordable GLP-1 option available
• Medicare patients — who have historically had limited coverage for anti-obesity medications
• People who need something now — while waiting for prior authorization approvals for newer medications
• Cash-pay patients — who are paying completely out of pocket

The honest trade-off: You’re getting a less potent medication that requires daily injections instead of weekly. The weight loss will be more modest than semaglutide or tirzepatide. But you’re getting a proven GLP-1 medication with 15+ years of safety data at a fraction of the price. For many people, affordable access to a good medication beats no access to a great one.

---

Cost and Access (Branded Versions)

NovoCare Savings Programs

Novo Nordisk offers savings programs for both branded products:

• Victoza savings card: Eligible patients with commercial insurance can pay as little as $25/month (up to $100 savings per one-month supply)
• Saxenda savings card: Similar structure — as little as $25/month for eligible commercially insured patients
• Patient Assistance Program (PAP): NovoCare provides medications at no cost for eligible uninsured patients meeting income requirements. Contact NovoCare at 1-866-310-7549.[10]

Government insurance exclusion: As with all manufacturer savings cards, Medicare, Medicaid, TRICARE, and VA beneficiaries are not eligible.

---

Storage

The 30-day window after first use is important to track — since these are multi-dose pens, they’ll sit around longer than a single-use pen would. Mark the date you first use a pen.[11]

---

Who Liraglutide Is Best For

Every medication has a profile of the person it serves best. For liraglutide in 2026, that person:

Values an extensive safety track record. Liraglutide has been in clinical use since 2010 — longer than any other currently available GLP-1 medication. For people (or their providers) who want the longest possible history of real-world safety data, that matters.

Needs an affordable GLP-1 option. With generics now available, liraglutide is the most accessible GLP-1 medication from a cost perspective. If the newer medications aren’t covered by your insurance or aren’t financially feasible, generic liraglutide opens a door that was previously closed.

Can manage daily injections. This is the flip side of liraglutide’s practicality — you inject every single day. If a weekly injection sounds dramatically easier (and for most people, it is), the newer medications have an undeniable convenience advantage.

Doesn’t need maximum weight loss. If your provider thinks an 8% weight loss would be clinically meaningful for you — improving blood pressure, blood sugar, joint health, sleep quality — liraglutide can deliver that. If the goal is dramatic weight reduction, the newer medications will likely get you further.

---

The Bottom Line

Liraglutide is the elder statesman of the GLP-1 world — the medication that proved this class works, helped establish the cardiovascular benefits that newer trials confirmed, and now offers something the newer drugs can’t: generic availability and a 15+ year safety record.

It’s not the most potent option anymore. The daily injection schedule is more demanding than the weekly alternatives. And the weight loss numbers don’t match what semaglutide and tirzepatide can achieve. But for the right person — especially someone who needs an affordable entry point into GLP-1 treatment — liraglutide remains a legitimate and well-proven option.

If you’re choosing between liraglutide and the newer medications, the decision usually comes down to three things: what your insurance covers, whether daily versus weekly injections matters to you, and how much weight loss you and your provider are targeting. There’s no wrong answer — just the one that fits your situation.

---